|
IL47062A
(en)
|
1975-04-10 |
1979-07-25 |
Yeda Res & Dev |
Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
|
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
DE3587500T2
(de)
|
1984-12-04 |
1993-12-16 |
Lilly Co Eli |
Tumorbehandlung bei Säugetieren.
|
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
|
US4665007A
(en)
|
1985-08-19 |
1987-05-12 |
International Business Machines Corporation |
Planarization process for organic filling of deep trenches
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
IL85746A
(en)
|
1988-03-15 |
1994-05-30 |
Yeda Res & Dev |
Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
|
|
FI891226L
(fi)
|
1988-04-28 |
1989-10-29 |
Univ Leland Stanford Junior |
Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
FI903489A7
(fi)
|
1988-11-11 |
1990-07-10 |
Medical Res Council |
Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
|
|
WO1990008187A1
(en)
|
1989-01-19 |
1990-07-26 |
Dana Farber Cancer Institute |
Soluble two domain cd2 protein
|
|
CA2046909A1
(en)
|
1989-03-21 |
1990-09-22 |
Mark D. Howell |
Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
FI920139A0
(fi)
|
1989-07-14 |
1992-01-13 |
Autoimmune Inc |
Foerfaranden foer behandling och foerfindrande av autoimmun uveoretinitis hos daeggdjur.
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
US5144088A
(en)
|
1991-04-26 |
1992-09-01 |
Aristech Chemical Corporation |
Manufacture of neopentyl glycol (I)
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
EP0604580A1
(en)
|
1991-09-19 |
1994-07-06 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US20030180290A1
(en)
|
1995-06-07 |
2003-09-25 |
Idec Pharmaceuticals Corporation |
Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6001358A
(en)
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
UA76934C2
(en)
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
|
ES2293661T3
(es)
|
1996-11-27 |
2008-03-16 |
Genentech, Inc. |
Purificacion por afinidad de polipeptido en una matriz de proteinas a.
|
|
EP1972194A1
(en)
|
1996-12-03 |
2008-09-24 |
Amgen Fremont Inc. |
Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
ATE230277T1
(de)
|
1997-06-13 |
2003-01-15 |
Genentech Inc |
Stabilisierte antikörperformulierung
|
|
US6991790B1
(en)
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
|
JP2002506353A
(ja)
|
1997-06-24 |
2002-02-26 |
ジェネンテック・インコーポレーテッド |
ガラクトシル化糖タンパク質の方法及び組成物
|
|
US20040191256A1
(en)
|
1997-06-24 |
2004-09-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
CA2307166A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
|
WO1999029888A1
(en)
|
1997-12-05 |
1999-06-17 |
The Scripps Research Institute |
Humanization of murine antibody
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
JP4334141B2
(ja)
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
ATE370961T1
(de)
|
1998-05-06 |
2007-09-15 |
Genentech Inc |
Reinigung von antikörpern durch ionenaustauschchromatographie
|
|
PT1974747E
(pt)
|
1998-08-11 |
2012-09-05 |
Biogen Idec Inc |
Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
|
|
ES2351149T3
(es)
|
1998-11-09 |
2011-02-01 |
Biogen Idec Inc. |
Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica.
|
|
MXPA01004649A
(es)
|
1998-11-09 |
2002-05-06 |
Idec Pharma Corp |
Tratamiento con anticuerpo quimerico anti-cd20 para pacientes que reciben transplantes de medula osea o celulas madre de sangre periferica.
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
JP2002537362A
(ja)
|
1999-02-22 |
2002-11-05 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
ビオチン化ケモカイン抗体複合体
|
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
|
IL146005A0
(en)
|
1999-05-07 |
2002-07-25 |
Genentech Inc |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
EP1216056A1
(en)
|
1999-07-12 |
2002-06-26 |
Genentech Inc. |
Blocking immune response to a foreign antigen using an antagonist which binds to cd20
|
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
KR100797667B1
(ko)
|
1999-10-04 |
2008-01-23 |
메디카고 인코포레이티드 |
외래 유전자의 전사를 조절하는 방법
|
|
CA2388245C
(en)
|
1999-10-19 |
2012-01-10 |
Kyowa Kirin Co., Ltd. |
The use of serum-free adapted rat cells for producing heterologous polypeptides
|
|
US20020006404A1
(en)
|
1999-11-08 |
2002-01-17 |
Idec Pharmaceuticals Corporation |
Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
|
KR20020072277A
(ko)
|
1999-11-08 |
2002-09-14 |
아이덱 파마슈티칼즈 코포레이션 |
항-cd20 항체 및/또는 화학요법 및 방사선요법과결합하여 항-cd40l 항체를 이용한 b세포 악성종양의치료방법
|
|
US20020028178A1
(en)
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
|
GB9926529D0
(en)
|
1999-11-09 |
2000-01-12 |
Ks Biomedix Ltd |
Targeting agents
|
|
JP2003516755A
(ja)
|
1999-12-15 |
2003-05-20 |
ジェネンテック・インコーポレーテッド |
ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
|
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
|
EP1283722A1
(en)
|
2000-03-31 |
2003-02-19 |
Idec Pharmaceuticals Corporation |
Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
|
|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
WO2001080884A1
(en)
|
2000-04-25 |
2001-11-01 |
Idec Pharmaceuticals Corporation |
Intrathecal administration of rituximab for treatment of central nervous system lymphomas
|
|
AU6836301A
(en)
|
2000-06-20 |
2002-01-02 |
Idec Pharma Corp |
Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
JP2004502742A
(ja)
|
2000-07-12 |
2004-01-29 |
アイデック ファーマスーティカルズ コーポレイション |
B細胞を消滅させる抗体及び免疫調節抗体を併用するb細胞悪性疾患の治療関連出願
|
|
WO2002022212A2
(en)
|
2000-09-18 |
2002-03-21 |
Idec Pharmaceuticals Corporation |
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
CN103333860B
(zh)
|
2000-10-06 |
2015-07-08 |
协和发酵麒麟株式会社 |
产生抗体组合物的细胞
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
AU2002213357A1
(en)
|
2000-10-20 |
2002-05-06 |
Idec Pharmaceuticals Corporation |
Variant igg3 rituxan r and therapeutic use thereof
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
DE60131456T2
(de)
|
2000-11-30 |
2008-07-10 |
Medarex, Inc., Milpitas |
Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
|
|
US20030211107A1
(en)
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20030103971A1
(en)
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
CA2436180C
(en)
|
2001-01-31 |
2011-11-08 |
Idec Pharmaceutical Corporation |
Immunoregulatory antibodies and uses thereof
|
|
JP4679035B2
(ja)
|
2001-04-02 |
2011-04-27 |
ジェネンテック, インコーポレイテッド |
併用療法
|
|
EP1383800A4
(en)
|
2001-04-02 |
2004-09-22 |
Idec Pharma Corp |
RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
|
|
EP1423510A4
(en)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
|
|
IL159422A0
(en)
|
2001-09-20 |
2004-06-01 |
Cornell Res Foundation Inc |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
US20030180292A1
(en)
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
|
EP1498491A4
(en)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
|
|
KR20050000380A
(ko)
|
2002-04-09 |
2005-01-03 |
교와 핫꼬 고교 가부시끼가이샤 |
게놈이 개변된 세포
|
|
WO2003085102A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
|
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
|
WO2003084570A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
|
|
EP1513879B1
(en)
|
2002-06-03 |
2018-08-22 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
KR100944575B1
(ko)
|
2002-10-17 |
2010-02-25 |
젠맵 에이/에스 |
Cd20에 대한 인간 모노클로날 항체
|
|
WO2004042072A2
(en)
|
2002-11-01 |
2004-05-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
|
|
US20050058649A1
(en)
|
2002-12-02 |
2005-03-17 |
Landes Gregory M. |
Antibodies directed to phospholipase A2 and uses thereof
|
|
WO2004060053A2
(en)
|
2002-12-16 |
2004-07-22 |
Genentech, Inc. |
Transgenic mice expressing human cd20
|
|
HUE035898T2
(en)
|
2002-12-16 |
2018-05-28 |
Genentech Inc |
Immunoglobulin variants and their applications
|
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
KR101498588B1
(ko)
|
2003-01-22 |
2015-03-05 |
로슈 글리카트 아게 |
융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
|
|
WO2004065569A2
(en)
|
2003-01-23 |
2004-08-05 |
The Regents Of The University Of California |
Multi-functional antibodies
|
|
WO2004065417A2
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
BRPI0408317A
(pt)
|
2003-03-14 |
2006-03-07 |
Pharmacia Corp |
anticorpos do receptor de igf-i para o tratamento de cáncer
|
|
ME00426B
(me)
|
2003-04-09 |
2011-10-10 |
Genentech Inc |
Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
|
|
US20050163775A1
(en)
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
ES2537738T3
(es)
|
2003-06-05 |
2015-06-11 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
|
WO2005017529A1
(en)
|
2003-07-29 |
2005-02-24 |
Genentech, Inc. |
Assay for human anti cd20 antibodies and uses therefor
|
|
US20050042664A1
(en)
|
2003-08-22 |
2005-02-24 |
Medimmune, Inc. |
Humanization of antibodies
|
|
EP1660129A2
(en)
|
2003-08-29 |
2006-05-31 |
Genentech, Inc. |
Anti-cd20 therapy of ocular disorders
|
|
JPWO2005035586A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
融合蛋白質組成物
|
|
CA2542125A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
|
|
HUE038955T2
(hu)
|
2003-11-05 |
2018-12-28 |
Roche Glycart Ag |
Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
|
|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
|
JP2007514787A
(ja)
|
2003-12-19 |
2007-06-07 |
ジェネンテック・インコーポレーテッド |
自己免疫疾患の治療におけるcd20の検出
|
|
AU2004303848A1
(en)
|
2003-12-19 |
2005-07-07 |
Genentech, Inc. |
Detection of CD20 in transplant rejection
|
|
JP4503617B2
(ja)
|
2003-12-23 |
2010-07-14 |
ライナット ニューロサイエンス コーポレイション |
アゴニスト抗trkC抗体および該抗体を用いる方法
|
|
AU2005214988A1
(en)
|
2004-02-17 |
2005-09-01 |
Absalus, Inc. |
Super-humanized antibodies against respiratory syncytial virus
|
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
WO2005100402A1
(en)
|
2004-04-13 |
2005-10-27 |
F.Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
|
BRPI0509412A
(pt)
|
2004-04-16 |
2007-09-04 |
Genentech Inc |
método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
|
|
RU2006140377A
(ru)
|
2004-04-16 |
2008-05-27 |
Дженентек, Инк. (Us) |
Способ усиления уничтожения в-клеток
|
|
ZA200608572B
(en)
|
2004-04-16 |
2008-06-25 |
Genentech Inc |
Assay for antibodies
|
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
RU2006142857A
(ru)
|
2004-05-05 |
2008-06-10 |
Дженентек, Инк. (Us) |
Профилактика аутоиммунного заболевания
|
|
EP1769243A2
(en)
|
2004-05-15 |
2007-04-04 |
Genentech, Inc. |
Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
|
|
JP2008501706A
(ja)
|
2004-06-04 |
2008-01-24 |
ジェネンテック・インコーポレーテッド |
疾患の治療方法
|
|
ZA200609978B
(en)
|
2004-06-04 |
2008-08-27 |
Genentech Inc |
Method for treating lupus
|
|
SG183012A1
(en)
|
2004-06-04 |
2012-08-30 |
Genentech Inc |
Method for treating multiple sclerosis
|
|
US7501121B2
(en)
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
|
US20080008719A1
(en)
|
2004-07-10 |
2008-01-10 |
Bowdish Katherine S |
Methods and compositions for the treatment of prostate cancer
|
|
US20060062787A1
(en)
|
2004-07-22 |
2006-03-23 |
Genentech, Inc. |
Method for treating Sjogren's syndrome
|
|
CA2577133A1
(en)
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
JP2008513367A
(ja)
|
2004-09-08 |
2008-05-01 |
ジェネンテック・インコーポレーテッド |
デスレセプターリガンド及びcd20抗体の使用方法
|
|
RU2007112952A
(ru)
|
2004-09-08 |
2008-10-20 |
Дженентек, Инк. (Us) |
Способы применения лигандов рецепторов смерти и cd20-антител
|
|
WO2006031825A2
(en)
|
2004-09-13 |
2006-03-23 |
Macrogenics, Inc. |
Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
|
CN101087807A
(zh)
|
2004-10-05 |
2007-12-12 |
健泰科生物技术公司 |
治疗血管炎的方法
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
EP1838348B1
(en)
|
2004-12-15 |
2013-06-26 |
Janssen Alzheimer Immunotherapy |
Humanized amyloid beta antibodies for use in improving cognition
|
|
NZ555286A
(en)
|
2004-12-17 |
2010-04-30 |
Genentech Inc |
Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
|
|
EP2290088A1
(en)
|
2004-12-22 |
2011-03-02 |
Genentech, Inc. |
Methods for producing soluble multi-menbrane-spanning proteins
|
|
US20060188495A1
(en)
|
2005-01-13 |
2006-08-24 |
Genentech, Inc. |
Treatment method
|
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
TW200714289A
(en)
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
AR053579A1
(es)
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
|
CA2607475A1
(en)
|
2005-04-22 |
2006-11-02 |
Genentech, Inc. |
Method for treating dementia or alzheimer's disease with a cd20 antibody
|
|
EP1883424A2
(en)
|
2005-05-18 |
2008-02-06 |
Biogen Idec Inc. |
Methods for treating fibrotic conditions
|
|
US7601335B2
(en)
|
2005-05-20 |
2009-10-13 |
Genentech, Inc. |
Pretreatment of a biological sample from an autoimmune disease subject
|
|
KR20080032065A
(ko)
|
2005-06-03 |
2008-04-14 |
제넨테크, 인크. |
푸코실화 수준이 조절된 항체의 생성 방법
|
|
US8219149B2
(en)
|
2005-06-29 |
2012-07-10 |
Nokia Corporation |
Mobile communication terminal
|
|
AU2006290433B2
(en)
|
2005-08-26 |
2012-06-07 |
Roche Glycart Ag |
Modified antigen binding molecules with altered cell signaling activity
|
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
CA2629306A1
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
WO2007064919A2
(en)
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
US20070136826A1
(en)
|
2005-12-02 |
2007-06-14 |
Biogen Idec Inc. |
Anti-mouse CD20 antibodies and uses thereof
|
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
CA2650730A1
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
|
EP2016101A2
(en)
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
|
PT2032606E
(pt)
|
2006-05-30 |
2014-02-05 |
Genentech Inc |
Anticorpos e imunoconjugados e respetivas utilizações
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
KR20070122316A
(ko)
|
2006-06-26 |
2007-12-31 |
(주) 에스바이오메딕스 |
주사용 인체 연조직 충전제 및 이의 제조 방법
|
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
CA2682406A1
(en)
|
2007-04-02 |
2008-10-09 |
Genentech, Inc. |
Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
|
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
|
US20090004189A1
(en)
|
2007-06-18 |
2009-01-01 |
Genentech, Inc. |
Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
|
|
EP2586788B1
(en)
|
2007-07-09 |
2017-11-29 |
Genentech, Inc. |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
|
WO2009007750A1
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
|
|
US20110243931A1
(en)
|
2007-09-02 |
2011-10-06 |
Thomas Friess |
Combination therapy with type i and type ii anti-cd20 antibodies
|
|
GB0718684D0
(en)
|
2007-09-24 |
2007-10-31 |
Roche Products Ltd |
Treatment method
|
|
US20090214561A1
(en)
|
2007-09-24 |
2009-08-27 |
David Robert Close |
Treatment method
|
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
|
US20090110688A1
(en)
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
|
HUE024877T2
(en)
|
2007-10-30 |
2016-02-29 |
Genentech Inc |
Antibody purification by cation exchange chromatography
|
|
US20120030144A1
(en)
|
2007-11-08 |
2012-02-02 |
Pikamab, Inc. |
Methods for doing business using biomarkers
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
WO2009080541A1
(en)
|
2007-12-21 |
2009-07-02 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
|
KR20100102172A
(ko)
|
2007-12-21 |
2010-09-20 |
제넨테크, 인크. |
리툭시마브-난치성 류마티스성 관절염 환자의 요법
|
|
CN101945890A
(zh)
|
2007-12-21 |
2011-01-12 |
健泰科生物技术公司 |
抗cd20抗体的结晶
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
KR20100107501A
(ko)
|
2008-01-18 |
2010-10-05 |
메디뮨 엘엘씨 |
부위 특이적 접합을 위한 시스테인 조작 항체
|
|
BRPI0909227B8
(pt)
|
2008-03-25 |
2021-05-25 |
Roche Glycart Ag |
uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)
|
|
EP2474323A3
(en)
|
2008-03-26 |
2012-10-10 |
Novartis AG |
Imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
|
|
WO2009134738A1
(en)
|
2008-04-29 |
2009-11-05 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
|
WO2010056893A1
(en)
|
2008-11-13 |
2010-05-20 |
Imclone Llc |
Humanization and affinity-optimization of antibodies
|
|
BRPI0916072A2
(pt)
|
2008-11-17 |
2015-11-10 |
Genentech Inc |
"uso de uma formulação, formulação farmacêutica, usos de um anticorpo 2h7 humanizado, método, método para aumentar a biodisponibilidade de um anticorpo e método de diálise in vitro"
|
|
KR20110097772A
(ko)
|
2008-11-17 |
2011-08-31 |
제넨테크, 인크. |
생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
|
|
AR075982A1
(es)
|
2009-03-31 |
2011-05-11 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
|
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
|
PT2417156E
(pt)
|
2009-04-07 |
2015-04-29 |
Roche Glycart Ag |
Anticorpos trivalentes, biespecíficos
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
SG176219A1
(en)
|
2009-05-27 |
2011-12-29 |
Hoffmann La Roche |
Tri- or tetraspecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
|
US9050375B2
(en)
|
2009-07-06 |
2015-06-09 |
Hoffmann-La Roche, Inc. |
Bi-specific digoxigenin binding antibodies
|
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
|
BR112012003066A2
(pt)
|
2009-08-14 |
2016-11-16 |
Roche Glycart Ag |
uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado
|
|
JP5996429B2
(ja)
|
2009-09-03 |
2016-09-21 |
ジェネンテック, インコーポレイテッド |
関節リウマチの治療、診断及びモニターするための方法
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
US20130089554A1
(en)
|
2009-12-29 |
2013-04-11 |
Emergent Product Development Seattle, Llc |
RON Binding Constructs and Methods of Use Thereof
|
|
WO2011131749A1
(en)
|
2010-04-23 |
2011-10-27 |
Glaxo Group Limited |
New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
|
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
GB201012217D0
(en)
|
2010-07-21 |
2010-09-08 |
Republic Polytechnic |
Compounds for photodynamic therapy
|
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
JP2014502607A
(ja)
|
2011-01-03 |
2014-02-03 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗dig抗体およびペプチドと結合体化しているジゴキシゲニンの複合体の薬学的組成物
|
|
LT2691417T
(lt)
|
2011-03-29 |
2018-10-25 |
Roche Glycart Ag |
Antikūno fc variantai
|
|
US8592156B2
(en)
|
2011-08-08 |
2013-11-26 |
Roche Molecular Systems, Inc. |
Predicting response to anti-CD20 therapy in DLBCL patients
|
|
US20140212425A1
(en)
*
|
2011-12-05 |
2014-07-31 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
|
EP2791165A4
(en)
|
2011-12-12 |
2015-08-05 |
Pikamab Inc |
PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY
|
|
US9527927B2
(en)
|
2011-12-20 |
2016-12-27 |
Medimmune, Llc |
Modified polypeptides for bispecific antibody scaffolds
|
|
WO2013157953A1
(en)
|
2012-04-20 |
2013-10-24 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
WO2013177062A2
(en)
|
2012-05-21 |
2013-11-28 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
|
SG11201407420RA
(en)
|
2012-07-04 |
2015-02-27 |
Hoffmann La Roche |
Covalently linked antigen-antibody conjugates
|
|
EP3919079A1
(en)
|
2012-09-07 |
2021-12-08 |
Genentech, Inc. |
Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
|
|
ES2693370T3
(es)
|
2013-05-02 |
2018-12-11 |
F. Hoffmann-La Roche Ag |
Politerapia de un anticuerpo CD20 afucosilado con un conjugado de anticuerpo CD22-fármaco
|
|
CN105793251B
(zh)
|
2013-12-05 |
2018-10-12 |
豪夫迈·罗氏有限公司 |
具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
|
|
HUE050159T2
(hu)
*
|
2013-12-17 |
2020-11-30 |
Genentech Inc |
Anti-CD3 antitestek és alkalmazási eljárások
|
|
WO2015101586A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
|
CN106687476B
(zh)
|
2014-06-26 |
2020-11-13 |
豪夫迈·罗氏有限公司 |
抗brdu抗体及使用方法
|
|
CN116196414A
(zh)
|
2015-05-11 |
2023-06-02 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
|
WO2017004091A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
FI3922279T3
(fi)
*
|
2016-08-30 |
2025-02-04 |
Dana Farber Cancer Inst Inc |
Lääkkeenantokoostumuksia ja niiden käyttötapoja
|
|
CN110551221B
(zh)
*
|
2019-07-02 |
2021-03-05 |
广州爱思迈生物医药科技有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
ES3064633T3
(en)
|
2019-09-12 |
2026-04-28 |
Hoffmann La Roche |
Compositions and methods of treating lupus nephritis
|
|
EP4454652A3
(en)
|
2021-03-15 |
2025-05-21 |
F. Hoffmann-La Roche AG |
Compositions and methods for treating lupus nephritis
|